Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GAPDHP26 is a processed pseudogene mapped in the human genome, originating from retrotransposition of mRNA of the functional parent gene, GAPDH[1][2]. Unlike its parent gene, it does not produce a functional enzyme and is generally considered genomically inactive, although some pseudogenes exhibit transcriptional activity under select conditions. Pseudogenes such as GAPDHP26 provide insight into the molecular evolution and retrotranspositional history of the genome, but lack defined roles in cellular pathways or disease. GAPDHP26 is annotated as a pseudogene in genomic databases and is not directly implicated in biological functions, molecular pathogenesis, or drug therapy[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde-3-phosphate dehydrogenase pseudogene 26 (GAPDHP26).